L-Prolinamide, N-(4-amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-((1S)-2-carboxy-1-formylethyl)- | 244133-31-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: L-Prolinamide, N-(4-amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-((1S)-2-carboxy-1-formylethyl)-
• 英文别名: (3S)-3-[[(2S)-1-[(2S)-2-[(4-amino-3-chlorobenzoyl)amino]-3,3-dimethylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoic acid
• CAS: 244133-31-1
• 化学式: C₂₂H₂₉ClN₄O₆
• 分子量: 480.9
• InChiKey: SOZONDBMOYWSRW-QANKJYHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  159
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
  申请人：Leblanc Andrea

  公开号：US11160788B2

  公开（公告）日：2021-11-02

  Described herein are methods for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating a neurological condition (e.g., a neurodegenerative disease (e.g., Alzheimer's disease)) in a subject, based on caspase-1 inhibition. Also described herein are methods for preventing, delaying the onset or reducing the severity of, preventing or reversing the progression of, or treating cognitive impairment in a subject, based on caspase-1 inhibition. Corresponding uses and kits are also described. In an embodiment, the caspase-1 inhibitor is VX-765 or a pharmaceutically acceptable salt thereof.

  本文描述了基于caspase-1抑制的预防、延迟发病或降低严重程度、预防或逆转进展或治疗受试者神经系统疾病（如神经退行性疾病（如阿尔茨海默病））的方法。本文还描述了基于caspase-1抑制的预防、延缓发病或减轻严重程度、预防或逆转进展或治疗受试者认知障碍的方法。还描述了相应的用途和试剂盒。在一个实施方案中，caspase-1抑制剂是VX-765或其药学上可接受的盐。
• CASPASE-1 INHIBITION AND USES THEREOF FOR PREVENTION AND TREATMENT OF NEUROLOGICAL CONDITIONS
  申请人：Leblanc, Andrea

  公开号：EP3558335A1

  公开（公告）日：2019-10-30
• Controlled release formulations
  申请人：Kadiyala Nikolaevna Irina

  公开号：US20080070972A1

  公开（公告）日：2008-03-20

  The invention relates to a controlled release formulation for an oral cytokine inhibitor of interleukin-1 beta converting enzyme.
• Methods for monitoring IL-18
  申请人：Roy Amit

  公开号：US20090215856A1

  公开（公告）日：2009-08-27

  This invention relates to methods for monitoring IL-18.
• CONTROLLED RELEASE FORMULATIONS
  申请人：Kadiyala Irina Nikolaevna

  公开号：US20110021598A1

  公开（公告）日：2011-01-27

  The invention relates to a controlled release formulation for an oral cytokine inhibitor of interleukin-1 beta converting enzyme.